Calidi Biotherapeutics stock was up 171.84% in pre-market trading on Wednesday, following a 39.47% rally yesterday. However, ...

Calidi Biotherapeutics Inc. CLDI stock surged by 39.47% in the after-hours trading session on Tuesday. The stock price ...

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today ...

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today ...

Ladenburg Thalmann & Co, Inc. is acting as the exclusive placement agent for the offering.

Calidi Biotherapeutics appointed new CEO and CMO, announced clinical trial progress, and reported financial results for Q1 2025.

Calidi Biotherapeutics, Inc. announced the pricing of its public offering of 5,000,000 shares of common stock at $0.85 per share, with anticipated gross proceeds of approximately $4.25 million.

CALIDI BIOTHERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands except for par value data)March 31, 2025 December 31, 2024 (Unaudited) ASSETS CURRENT ASSETS ...

About Calidi Biotherapeutics. Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer.

About Calidi Biotherapeutics. Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer.

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted ...